Highlights of Sarcoma Research Presented at ASCO 2024 With Richard Riedel, MD

In this interview from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor Editorial Board member Dr. Richard Riedel briefs us on the notable updates in bone and soft tissue sarcoma research presented at the meeting, including:

  • The phase 3 MOTION study of vimseltinib for patients with tenosynovial giant cell tumor
  • The phase 2 SU2C-SARC032 trial of pembrolizumab plus radiation and surgery for patients with stage III sarcoma
  • Analyses of the DeFi study of nirogacestat for patients with progressing desmoid tumors

Dr. Riedel also reflects on the Dedifferentiated Liposarcoma Task Force he is currently co-chairing for i3 Health and shares a preview of topics that he and his co-panelists will be elaborating on in their upcoming position statement, including incidence and presenting symptoms, the need for pathologic expertise in making a diagnosis, multidisciplinary management for localized disease control, emerging therapies for patients with metastatic disease, and more!  

About Dr. Riedel

Richard Riedel, MD, is an Associate Professor in the Division of Medical Oncology at Duke University Medical Center and the Associate Director of Clinical and Translational Research for the Duke Sarcoma Program. His clinical practice is dedicated to the care of patients with bone and soft tissue sarcoma, and his research interests lie in identifying novel therapies for these patients. Dr. Riedel is a member of the National Comprehensive Cancer Network (NCCN) Soft Tissue Sarcoma Guidelines Panel member and the NCCN Gastrointestinal Stromal Tumor (GIST) Guidelines Panel, and he is active in educational initiatives for sarcoma treatment.

Banner ad

Related Articles

Responses

Your email address will not be published. Required fields are marked *